A mechanism-based model to describe the emergence of resistance in response to treatment with polymyxin B (PMB), fosfomycin, and meropenem against carbapenem-resistant Klebsiella pneumoniae (CRKP) using an in vitro dynamic infection model (IVDIM)

被引：0
|
作者：
Diep, John K. [1 ]
Garcia, Estefany [1 ]
El-Sheikh, Ahmed O. [1 ]
Rao, Gauri G. [1 ]
机构：
[1] UNC, Eshelman Sch Pharm, Chapel Hill, NC USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-089
引用
收藏
页码：S129 / S130
页数：2
相关论文
共 8 条
  • [1] A MECHANISM-BASED MODEL (MBM) TO DESCRIBE THE SYNERGISTIC EFFECT OF POLYMYXIN B (PMB) AND FOSFOMYCIN (FOF) IN KLEBSIELLA PNEUMONIAE (KP).
    Garcia, E.
    Sharma, R.
    Rao, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S21 - S21
  • [2] Investigation of in vitro efficacy of meropenem/ polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains
    Adaleti, Riza
    Nakipoglu, Yasar
    Calik, Seyma
    Arici, Neslihan
    Kansak, Nilgun
    Senbayrak, Seniha
    Aksaray, Sebahat
    ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, 2023, 70 (02) : 155 - 160
  • [3] Bacteriophage treatment is effective against carbapenem-resistant Klebsiella pneumoniae (KPC) in a neutropenic murine model of gastrointestinal translocation and renal infection
    Zagaliotis, Panagiotis
    Michalik-Provasek, Jordyn
    Mavridou, Eleftheria
    Naing, Ethan
    Vizirianakis, Ioannis S.
    Chatzidimitriou, Dimitrios
    Gill, Jason J.
    Walsh, Thomas J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (02)
  • [4] Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis
    Borjan, Jovan
    Meyer, Kevin A.
    Shields, Ryan K.
    Wenzler, Eric
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (01)
  • [5] Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study
    Guanhao Zheng
    Jiaqi Cai
    Liang Zhang
    Dayu Chen
    Linyu Wang
    Yusi Qiu
    Han Deng
    Hao Bai
    Xiaolan Bian
    Juan He
    Infectious Diseases and Therapy, 2022, 11 : 1917 - 1934
  • [6] Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study
    Zheng, Guanhao
    Cai, Jiaqi
    Zhang, Liang
    Chen, Dayu
    Wang, Linyu
    Qiu, Yusi
    Deng, Han
    Bai, Hao
    Bian, Xiaolan
    He, Juan
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (05) : 1917 - 1934
  • [7] Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model
    Hagihara, Mao
    Kato, Hideo
    Sugano, Toshie
    Okade, Hayato
    Sato, Nobuo
    Shibata, Yuichi
    Sakanashi, Daisuke
    Asai, Nobuhiro
    Koizumi, Yusuke
    Suematsu, Hiroyuki
    Yamagishi, Yuka
    Mikamo, Hiroshige
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (05)
  • [8] Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model
    Cai, Yiying
    Lim, Tze-Peng
    Teo, Jocelyn Qi-Min
    Sasikala, Suranthran
    Chan, Eric Chun Yong
    Hong, Yan Jun
    Lee, Winnie
    Tan, Thean Yen
    Tan, Thuan Tong
    Koh, Tse Hsien
    Hsu, Li Yang
    Kwa, Andrea L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (01)
1